权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Genetic Modifiers of Retinal Disease

视网膜疾病的基因修饰

基本信息

批准号：
10375022
负责人：
Patsy M Nishina
金额：
$ 60.3万
依托单位：
JACKSON LABORATORY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-03-01 至 2027-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10375022
关键词：
Ablation Address Adult Affect Age of Onset Alleles Animal Model Appearance Atrophic Automobile Driving Biological Blindness CRISPR/Cas technology Cells Characteristics Child Clinical Coats&apos disease Cystoid Macular Edema Development Diagnosis Disease Enhancers Environmental Exposure Environmental Risk Factor Family Genes Genetic Genome Genotype Heritability Human Knock-out Knowledge Lead Leber&apos s amaurosis Leber&apos s disease Mediating Mendelian disorder Microphthalmos Modification Molecular Monoclonal Antibodies Mus Mutation Onset of illness Optic Disk Drusen Pathogenicity Pathologic Pathology Pathway Analysis Pathway interactions Patients Pattern Phenotype Pigmentation physiologic function Pigments Population Progressive Disease Protein Isoforms Public Health Reporting Resources Retina Retinal Detachment Retinal Diseases Retinitis Pigmentosa Retinoschisis Role Severities Severity of illness Specificity Telangiectasis Testing Therapeutic Therapeutic Intervention Tissues Treatment outcome Variant arteriole blind cell type cone-rod dystrophy differential expression disease phenotype disease prognosis early onset effective therapy gene augmentation therapy improved insight macula mouse model mutant personalized medicine pre-clinical precision medicine preservation prevent response targeted treatment therapeutic evaluation therapeutic target treatment response

项目摘要

PROJECT SUMMARY/ABSTRACT Heritable retinal disorders, for which effective treatments are generally unavailable, contributes to the 1.02 million adults who are blind in the US. Among children, the heritable disease - Leber Congenital Amaurosis, accounts for 20% of blindness, and 10-15%of those are caused by mutations in the CRB1 gene. In addition to LCA, CRB1 mutations can also cause congenital or early-onset retinitis pigmentosa (RP), a more slowly progressive disease. CRB1 RP variants are sometimes associated with unique disease features, such as retinal telangiectasia with or without exudative retinal detachment (Coat's disease), a loss of RPE pigmentation except near arterioles (preservation of para-arteriolar RPE or PPRPE), pigment paravenous chorioretinal atrophy, cone-rod dystrophy, nanophthalmos with optic disc drusen, retinoschisis, cystoid macular edema, and macular dystrophic disease. The cause of the wide range of disease phenotypes associated with CRB1 mutations is not fully understood. Genotype-phenotype correlations that could explain the disease spectrum have not been detected among patients bearing CRB1 mutations, suggesting that environmental factors or genetic background modifiers contribute to the variability in the disease phenotypes observed. Another potential contributor to the phenotypic variability in disease presentation are Crb1 isoforms which have recently been shown to have spatially and temporally distinct expression patterns. Clearly, understanding the reasons for the variability and the mechanisms underlying the observed pathologies is extremely important for developing effective therapies. In this proposal, we will test the hypothesis that pathological changes due to Crb1 mutations depend upon the isoform affected and the genetic background on which it occurs, and their potential interactions. We will identify the molecular basis of genetic modifiers that enhance or suppress Crb1rd8 associated disease phenotypes or are epistatic upon Crb1rd8. Through the use of mouse models with isoform specific knockout alleles and controlled genetic backgrounds, we will determine their contribution to disease variability and the mechanisms through which they function. These studies address a critical unmet need for acquiring the basic biological knowledge necessary to develop effective therapies that can target the pre-symptomatic stage to prevent, delay onset or decrease severity of the disease. Animal models serve an important and unique role to further our understanding of the genetic underpinnings of disease and as a resource to examine tissue pathology, and to perform pre-clinical therapeutic tests that cannot be readily conducted in humans.

项目总结/文摘